|
 |
|||||||
 |
PRESS RELEASES ADVENTRX Pharmaceuticals Commences cGMP Manufacturing of Thiovir™ SAN DIEGO – June 1, 2004 – ADVENTRX Pharmaceuticals, Inc. (Amex: ANX) announced today that it has begun cGMP (current Good Manufacturing Practices) production of the antiviral drug, Thiovir, in preparation for an Investigational New Drug (IND) application filing with the FDA. Thiovir is being manufactured by deCODE genetics' (Nasdaq:DCGN) chemistry facility, based in Lemont, IL. "The successful launch of cGMP manufacturing for Thiovir represents an important step towards moving this compound into the clinic," said Joan M. Robbins, Ph.D., ADVENTRX Pharmaceuticals' Chief Technical Officer. "In addition to this manufacturing effort, we expect to complete other necessary components for an IND filing with the FDA in QIV 2004." Thiovir is an orally-delivered prodrug for the broad spectrum antiviral drug, foscarnet, which is an IV-delivered treatment for opportunistic infections in HIV-infected patients. ADVENTRX intends to study Thiovir as a non nucleoside reverse transcriptase inhibitor (NNRTI) component of HAART (highly active antiretroviral therapy) for treatment of HIV/AIDS. deCODE's cGMP manufacturing facility, based in Woodridge, Illinois, conducts process chemistry optimization and cGMP manufacturing for pharmaceutical and biotechnology clients as well as for deCODE's proprietary drug development programs. About ADVENTRX ADVENTRX Pharmaceuticals, Inc. is a biopharmaceutical research and development company whose business strategy is to commercialize leading edge medical research through licensing agreements with prominent universities and research institutions. The Company focuses on cancer and antiviral research to launch products that either extend the usefulness of current therapies or replace marginal therapies with new approaches to treatment. More information on ADVENTRX can be found on the Company's website at www.adventrx.com. This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Such statements are made based on management's current expectations and beliefs. Actual results may vary from those currently anticipated based upon a number of factors, including uncertainties inherent in the drug development process, the timing and success of clinical trials, the validity of research results, and the receipt of necessary approvals from the United States Food and Drug Administration. The Company undertakes no obligation to release publicly any revisions, which may be made to reflect events or circumstances after the date hereof. Contacts: The Ruth Group Investors: Stephanie Carrington 646-536-7017 Media: Cynthia Isaac, Ph.D. 646-536-7028 |
